Antares Pharma  
Antares Pharma, Inc. (ATRS.US)主要从事医药用的注射器，以及外用凝胶的开发与产销，公司专利的产品有ATD凝胶、一次性迷你针头注射器，以及可重复使用的无针头注射系统。其中可重复使用的无针头注射系统已授权于TEVA，Ferring Pharmaceuticals及JCR Pharmaceuticals为TEVA的二个主要客户。

 
Antares Pharma focuses on self-administered parenteral pharmaceutical products and topical gel-based medicines. The Company is developing OTREXUP™ a combination product for the delivery of methotrexate using Medi-Jet™ technology for the treatment of rheumatoid arthritis poly-articular-course juvenile rheumatoid arthritis and psoriasis as well as VIBEX™ QS T for testosterone replacement therapy. The Company's technology platforms include VIBEX™ disposable Medi-Jet™ disposable multi-use pen injectors and Vision™ reusable needle-free injectors marketed as Tjet® and Zomajet® by Teva Pharmaceutical Industries Ltd (Teva) and Ferring Pharmaceuticals (Ferring) respectively. Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin® human growth hormone (hGH) VIBEX™ epinephrine and several other products. Antares Pharma’s partnership with Ferring includes Zomacton® hGH. In the U.S. Antares has received FDA approval for Gelnique 3%™ a treatment for overactive bladder that is marketed by Actavis. Elestrin® (estradiol gel) is FDA approved for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and is marketed in the U.S. by Meda Pharma. Antares Pharma has two facilities in the U.S. The Parenteral Products Group located in Minneapolis Minnesota directs the manufacturing and marketing of the Company’s reusable needle-free injection devices and related disposables and develops its disposable pressure-assisted Medi-Jet and pen injector systems. The Company’s corporate office and Product Development and Commercial Groups are located in Ewing New Jersey.